<DOC>
	<DOCNO>NCT00881530</DOCNO>
	<brief_summary>The objective current study investigate safety efficacy BI 10773 2 different dos compare Metformin Sitagliptin give 78 week different modality treatment patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Empagliflozin ( BI 10773 ) Type Two Diabetes ( T2D ) Patients , Open Label Extension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion : patient complete one double blind phase II trials 1245.9 1245.10 informed consent Exclusion criterion : patient meet withdrawal criterion precede trial significant hepatic impairment significant renal impairment creatinine clearance &lt; 50 ml/min contraindication Metformin patient treat Metformin premenopausal woman nurse pregnant practice acceptable method birth control drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>